These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
772 related articles for article (PubMed ID: 27114589)
1. Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers. Vasen H; Ibrahim I; Ponce CG; Slater EP; Matthäi E; Carrato A; Earl J; Robbers K; van Mil AM; Potjer T; Bonsing BA; de Vos Tot Nederveen Cappel WH; Bergman W; Wasser M; Morreau H; Klöppel G; Schicker C; Steinkamp M; Figiel J; Esposito I; Mocci E; Vazquez-Sequeiros E; Sanjuanbenito A; Muñoz-Beltran M; Montans J; Langer P; Fendrich V; Bartsch DK J Clin Oncol; 2016 Jun; 34(17):2010-9. PubMed ID: 27114589 [TBL] [Abstract][Full Text] [Related]
2. Pancreatic Cancer Surveillance in Carriers of a Germline Klatte DCF; Boekestijn B; Wasser MNJM; Feshtali Shahbazi S; Ibrahim IS; Mieog JSD; Luelmo SAC; Morreau H; Potjer TP; Inderson A; Boonstra JJ; Dekker FW; Vasen HFA; van Hooft JE; Bonsing BA; van Leerdam ME J Clin Oncol; 2022 Oct; 40(28):3267-3277. PubMed ID: 35658523 [TBL] [Abstract][Full Text] [Related]
3. Variation in precursor lesions of pancreatic cancer among high-risk groups. Potjer TP; Schot I; Langer P; Heverhagen JT; Wasser MN; Slater EP; Klöppel G; Morreau HM; Bonsing BA; de Vos Tot Nederveen Cappel WH; Bargello M; Gress TM; Vasen HF; Bartsch DK; ; Clin Cancer Res; 2013 Jan; 19(2):442-9. PubMed ID: 23172884 [TBL] [Abstract][Full Text] [Related]
4. High Growth Rate of Pancreatic Ductal Adenocarcinoma in Ibrahim IS; Wasser MN; Wu Y; Inderson A; de Vos Tot Nederveen Cappel WH; Morreau H; Hes FJ; Veenendaal RA; Putter H; Feshtali S; van Mil AM; Gruis NA; Tollenaar RA; Bergman W; Bonsing BA; Vasen HFA Cancer Prev Res (Phila); 2018 Sep; 11(9):551-556. PubMed ID: 29991580 [No Abstract] [Full Text] [Related]
5. Prevalence and Progression of Pancreatic Cystic Precursor Lesions Differ Between Groups at High Risk of Developing Pancreatic Cancer. Konings IC; Harinck F; Poley JW; Aalfs CM; van Rens A; Krak NC; Wagner A; Nio CY; Sijmons RH; van Dullemen HM; Vleggaar FP; Ausems MG; Fockens P; van Hooft JE; Bruno MJ; Pancreas; 2017 Jan; 46(1):28-34. PubMed ID: 27846136 [TBL] [Abstract][Full Text] [Related]
6. Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance. Canto MI; Almario JA; Schulick RD; Yeo CJ; Klein A; Blackford A; Shin EJ; Sanyal A; Yenokyan G; Lennon AM; Kamel IR; Fishman EK; Wolfgang C; Weiss M; Hruban RH; Goggins M Gastroenterology; 2018 Sep; 155(3):740-751.e2. PubMed ID: 29803839 [TBL] [Abstract][Full Text] [Related]
7. Surveillance Outcome and Genetic Findings in Individuals at High Risk of Pancreatic Cancer. Rosner G; Scapa E; Ziv T; Gluck N; Ben-Yehoyada M Clin Transl Gastroenterol; 2024 Feb; 15(2):e00668. PubMed ID: 38147532 [TBL] [Abstract][Full Text] [Related]
8. Long-term yield of pancreatic cancer surveillance in high-risk individuals. Overbeek KA; Levink IJM; Koopmann BDM; Harinck F; Konings ICAW; Ausems MGEM; Wagner A; Fockens P; van Eijck CH; Groot Koerkamp B; Busch ORC; Besselink MG; Bastiaansen BAJ; van Driel LMJW; Erler NS; Vleggaar FP; Poley JW; Cahen DL; van Hooft JE; Bruno MJ; Gut; 2022 Jun; 71(6):1152-1160. PubMed ID: 33820756 [TBL] [Abstract][Full Text] [Related]
11. Incidental findings in pancreas screening programs for high-risk individuals: Results from three European expert centers. Ibrahim IS; Brückner C; Carrato A; Earl J; Inderson A; de Vos Tot Nederveen Cappel WH; Mintziras I; Matthäi E; Figiel J; Wasser M; Moreau H; Bonsing B; Slater EP; Bartsch DK; Vasen HF United European Gastroenterol J; 2019 Jun; 7(5):682-688. PubMed ID: 31210946 [TBL] [Abstract][Full Text] [Related]
12. Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in Saldia A; Olson SH; Nunes P; Liang X; Samson ML; Salo-Mullen E; Marcell V; Stadler ZK; Allen PJ; Offit K; Kurtz RC Cancer Prev Res (Phila); 2019 Sep; 12(9):599-608. PubMed ID: 31337648 [TBL] [Abstract][Full Text] [Related]
13. EUS-based Pancreatic Cancer Surveillance in Katona BW; Long JM; Ahmad NA; Attalla S; Bradbury AR; Carpenter EL; Clark DF; Constantino G; Das KK; Domchek SM; Dudzik C; Ebrahimzadeh J; Ginsberg GG; Heiman J; Kochman ML; Maxwell KN; McKenna DB; Powers J; Shah PD; Wangensteen KJ; Rustgi AK Cancer Prev Res (Phila); 2021 Nov; 14(11):1033-1040. PubMed ID: 34341011 [TBL] [Abstract][Full Text] [Related]
14. The benefit of pancreatic cancer surveillance in carriers of germline BRCA1/2 pathogenic variants. Laish I; Schechter M; Dancour A; Lieberman S; Levi Z; Goldberg Y; Kedar I; Hasnis E; Half E; Levi GR; Katz L; Vainer ED; Genzel D; Aharoni M; Chen-Shtoyerman R; Abu-Freha N; Raitses-Gurevich M; Golan T; Bernstein-Molho R; Ben Yehoyada M; Gluck N; Rosner G Cancer; 2024 Jan; 130(2):256-266. PubMed ID: 37861363 [TBL] [Abstract][Full Text] [Related]
15. Dilemmas in the management of screen-detected lesions in patients at high risk for pancreatic cancer. Ibrahim IS; Bonsing BA; Swijnenburg RJ; Welling L; Veenendaal RA; Wasser MN; Morreau H; Inderson A; Vasen HF Fam Cancer; 2017 Jan; 16(1):111-115. PubMed ID: 27406244 [TBL] [Abstract][Full Text] [Related]
16. BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts. Lucas AL; Frado LE; Hwang C; Kumar S; Khanna LG; Levinson EJ; Chabot JA; Chung WK; Frucht H Cancer; 2014 Jul; 120(13):1960-7. PubMed ID: 24737347 [TBL] [Abstract][Full Text] [Related]
17. Risk of multiple pancreatic cancers in CDKN2A-p16-Leiden mutation carriers. Ibrahim I; Sibinga Mulder BG; Bonsing B; Morreau H; Farina Sarasqueta A; Inderson A; Luelmo S; Feshtali S; Potjer TP; de Vos Tot Nederveen Cappel W; Wasser M; Vasen HFA Eur J Hum Genet; 2018 Aug; 26(8):1227-1229. PubMed ID: 29769629 [TBL] [Abstract][Full Text] [Related]
19. Dilatation of the main pancreatic duct as first manifestation of small pancreatic ductal adenocarcinomas detected in a hereditary pancreatic cancer surveillance program. Vasen HFA; Boekestijn B; Ibrahim IS; Inderson A; Bonsing BA; de Vos Tot Nederveen Cappel WH; Feshtali S; Wasser MN HPB (Oxford); 2019 Oct; 21(10):1371-1375. PubMed ID: 30910317 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of pancreas surveillance: The CDKN2A-p16-Leiden cohort. Ibrahim IS; Vasen HFA; Wasser MNJM; Feshtali S; Bonsing BA; Morreau H; Inderson A; de Vos Tot Nederveen Cappel WH; van den Hout WB United European Gastroenterol J; 2023 Mar; 11(2):163-170. PubMed ID: 36785917 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]